Nemaura Medical Inc (NMRD)

[iddrisw]

Been out of this a while. Will be shorting if it goes back up

[Think4yourself1]

Shorting would be good right now knowing that the stock gets crushed in the January delisting. Iddrisw you still have shares of this? Worst stock I have ever owned. Glad I did not load up heavy on it.

[iddrisw]

Has anyone tried shorting this pos? May be a good short to bankruptcy.

[Think4yourself1]

What the hell did faz see in Dalkas Burston? Why does he always defend him? This company and management is a joke. I was going to buy more so glad I did not. No one will want to invest in this. What's going to happen when nemaura needs money and no one will fund them? May go bankrupt at this point??

[BigBill1]

The SP is .66 in part to unusually heavy selling before today's release of the 10Q. Like triple the volume. There is no way one can look at the level of trading right before a news event and not conclude there is inside trading occurring on a regular basis.

[Think4yourself1]

66 cents a share wow faz is a idiot. How he could allow this to happen? He should of marketed this with someone like dexcom or Abbott. At this point just break your contract with DBE and pay a fee. I feel so sorry for anyone who loaded up on this.

[BigBill1]

Here we go again, more delays! From todays 10Q:

Note 3: "As the Company now expects commercialization of the sugarBEAT device to occur in the first quarter ending June 30, 2020"

They are going by Nemaura's fiscal year, not calendar year.

So Dallas Burston won't be ready to launch until at least April, 2020. Due to the NASDAQ Rule 5550(a)(2) requiring listed securities to maintain a minimum closing bid price of $1.00 per share by January 11, 2020 and the continued delay by Dallas Burston I can easily see the SP going down into the .30's or worse over the next 4 months.

[Think4yourself1]

I remember how bullish everyone was on this stock thinking the only thing holding them back was ce approval. No one is going to want to f UK and them with no sales. How long till they need more money? Investors won't be buying anymore. Everyone is sick of all the broken promises. No way does this stock stay for 10 days straight at 1 or more before the January delesting. What the hell has faz been doing?

[Think4yourself1]

Faz needs to demand that DBE do there job. In my opinon the stock gets crushed in january. It gets crushed more when the launch gets delayed which is highly likely. Who else does DBE have as a client? FAZ should of used someone who would of marketed this aggressively. Most investors haven't given up on this. The ones who have it are just holding it at this price.

[BigBill1]

@Think4 Dallas Burston has the power avert the share value fiasco coming in January. All he has to do is commence commercialization of the android version ASAP and accept online "expressions of interest" for the soon to be released iOS version.
Then watch how fast the SP exceeds $1.

[Think4yourself1]

What's everyone's prediction on the stock in January reverse stock split or nasdaq delisting? Unless somehow faz and insiders can mulipinate the stock to be compliant by then which I dont see happening.

[iddrisw]

Yes stick to the real issues. I can agree with your take on the transactions especially if the launch is delayed again. I gave them the benefit of the doubt because their burn rate was minuscule and all the directors made less than $100000 per year.

[finesand]

In fact imho it is the very reason why they have this stupid partnership with DBE to seek validation which has held them back.

you answered my question.

No, I don't need to be PC and still can bring up the issue at hand,
while not personally being racist. It is reality very often.

IMHO the biggest problem are the related transactions, i.e. N. Pharma which they pay for services. I described how this could be utilized to grab cash from the public company or 'just' used as a short attack.

But I got curious in the sector of diabetes. Started some DD here and watching a little.

[iddrisw]

You definitely sound racist. These guys are all from from the UK even though faz is ethnically Bangladeshi. I don’t see what this has to do with anything. In fact imho it is the very reason why they have this stupid partnership with DBE to seek validation which has held them back.

[Maley63]

Can’t forget that possibly the main reason for not selling the product was due to lack of iOS mobile app.
They stated in the conference that they were working on getting this finished. The way Faz spoke about it seemed like he didn’t realize at the time that Android and Apple software don’t speak to each other.

Also not sure how you can read into this. I used to work for a 16mil/year, small company and was discussing sugarbeat to the big boss. He told me that he had invested in Nemaura Pharma as part of his share portfolio.

[finesand]

yes, as I have posted ...

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152069381

This could be a big issue, especially now knowing that the big owners just invested from 10c or below and did not participate in late raises.
Only the loan from one SH is a positive.

So the setup could be indeed to drain value from public to private,
DRYS comes into mind as one of the worst examples.
Here CEO milked the public company paying for services owned by family.

Still speculation!
However, the amount of these residuals especially in a related within arms reach deal must be disclosed.
(EROS is another bitter taster example, easy short attack surface, especially if showing weakness in biz execution.)

This N. Medical <-> N. Pharma relationship is quite fishy,
could allow owners to use N. Pharma to drain 'public' money into their private company?
- NMRD (Nemaura Medical) owns 100% of Region Green Limited
- Region Green Limited owns 100% of Dermal Diagnostic (Holdings) Limited.
- Dermal Diagnostic (Holdings) Limited owns 100% of DDL and 100% of Trial Clinic Limited (TCL)
- Nemaura Pharma (NP) is an affiliated Company not owned by NMRD.
- NMRD and Nemaura Pharma (NP) share same address and officials.
- NMRD outsources jobs to NP (money flow)
- NP also contracted to do the SugarBEAT manufacturing

[BigBill1]

@finesand One of the things that keep nagging at the back of my brain is the disclosure that their privately owned Nemaura Pharma will receive residuals from the sales of publicly owned Nemaura Medical in I believe it was in a recent quarterly report. It did not state the amount of the residual.
I can see a few scenarios of how this could end up screwing the SH.

[finesand]

Insider Ownership Value (Invested)

Because the insider ownership is still very strong

Ownership @ 221.7M OS fully diluted
- 2018-06-05 CEO Chowdhury 87.54M 39.49%
- 2018-06-05 Timol Bashir 27.08M 12.21%
- 2018-06-05 Ismail Sufyan 22.71M 10.34%
- 2017-12-31 Sze Tang Li 4.69M 2.12%

I needed to check how much they potentially have paid for ..

I also like to learn when and at which share price did the three insider purchase the 87.5M + 27M + 22.7M shares? This number hasn't changed (much) since the initial Form 3.
So I must assume these shares were acquired via an M&A transaction much earlier? This thought regarding CEO & Co valuing their ownership..

This especially under consideration of ongoing dilution ($19M ATM) and RS havoc .. like: Would they really care?

Let's look back ...

2018-01-25 Uplisting to NASDAQ from OTCQB

2014-08-12 F 3: CEO Chowdhury 87.54M shares
https://www.sec.gov/Archives/edgar/data/0001602078/000117337514000323/0001173375-14-000323-index.htm

2014-08-12 S-1/A (final, EFFECTed): 20M RESALE @ $0.10/sh
- SP started around $0.10/sh Dec 2014
- CEO Chowdhury 87.54M -> $8.75M max
- Timol Bashir 26.26M -> $2.26M max
https://www.sec.gov/Archives/edgar/data/1602078/000117337514000219/nemauras1a6.htm#SECURITYOWNERSHIP

The earliest final S-1/A from 2014 doesn't disclose how CEO got his shares, but he already started with his 87.54M shares at a resale price of $0.10.

Same for Bashir etc.

Not to look as a racists - which I am not,
but it didn't get unnoticed that the company's officers and owners somehow originate from another country than the UK. Is it Bangladesh?

Regardless, at 10c and probably less investment - besides their time, all officers still have quite some buffer compared to current SP.

Having read the lack of progress lately on sales, despite CE Mark and the generous loan from a shareholder below 10% rate (very bullish), they simply didn't start selling and even pushed the date out: 1Q20 (starting 4/1/20).

Therefor the product or production is not ready yet - I have to assume.

Please correct...

[finesand]

BigBill1- thank you.

A few papers supporting the MARD and other quality values might be helpful?
Yes, I read the FDA data paper 18/12/2018 https://nemauramedical.com/wp-content/uploads/2018/12/NMRD-Clinical-Presentation-18-Dec-2018.pdf

Yes, the CE approval gives some support. I agree.

Sadly no peer reviewed or independent lab confirmation of the numbers right?

The whole DallasB stuff is quite new to me and yes, disturbing.
Why giving such an 'interesting' party this opportunity for the US sales?
The website and re-branding is a disaster.

I also see that time to market has been broken a few times, I get the frustration.

Also possible QA issues with production .. The Pharma private sub and ofc clarification of costs and source of the insider shares.

Need to dig further ..

Yes yes, first 180 days $1 bid deficiency ends 2020-01-11.
Then they need a plan inclusive SH vote for RS to apply for the 2nd 180 days and so forth.

The private loan from one SH below 10% rate was nice of course, as the $19.39M ATM with MAXIM is still hanging over ones heads.
In this regard, the valuation of insiders shares might be important.

[BigBill1]

@finesand Reverse ionotophoresis has been proven. First with the GlucoWatch, which eventually failed because the battery was laying on the skin and causing burns, as opposed to sugarBeat which draws fluid into a cup shaped chamber. Reverse iontophoresis was further proven via CE approval two times for sugarBeat.

The only thing unproven is Dallas Burston's ability to market this product before what's left of shareholders value is destroyed on January 11th.

[finesand]

MOA 'Reverse Ionotophoresis' Proven?

One critical (personal) review paper https://www.nivglucose.com/The%20Pursuit%20of%20Noninvasive%20Glucose%206th%20Edition.pdf

mentions the risk that these devices may read sweat instead of 'bodily fluids' glucose ions, received by the anode.

Do they have anything peer reviewed or an independent lab validation test?

EDITED: You can find some papers on the issue also related to GlucoWatch, but has this concept being proven solid & stable and validated by an independent lab?

I am aware that if this would work with a convenient device (with longer battery power than 12h of course and one replacement battery for loading while wearing) .. it could be the holy grail (o8>

[finesand]

This N. Medical <-> N. Pharma relationship is quite fishy,
could allow owners to use N. Pharma to drain 'public' money into their private company?
- NMRD (Nemaura Medical) owns 100% of Region Green Limited
- Region Green Limited owns 100% of Dermal Diagnostic (Holdings) Limited.
- Dermal Diagnostic (Holdings) Limited owns 100% of DDL and 100% of Trial Clinic Limited (TCL)
- Nemaura Pharma (NP) is an affiliated Company not owned by NMRD.
- NMRD and Nemaura Pharma (NP) share same address and officials.
- NMRD outsources jobs to NP (money flow)
- NP also contracted to do the SugarBEAT manufacturing

I also like to learn when and at which share price did the three insider purchase the 87.5M + 27M + 22.7M shares? This number hasn't changed (much) since the initial Form 3.
So I must assume these shares were acquired via an M&A transaction much earlier? This thought regarding CEO & Co valuing their ownership..

.. and I forgot, why did they swap their common shares to preferred shares and back 2017-2018?

[Think4yourself1]

I suggest that nobody drop anymore money into this till after the January nasdaq delisting or reverse stock split. Either is further going to devalue the stock. Hoping there early 2020 launch dates are accurate but given there past history I'm not counting on it.

[WhiskyBusiness]

As in new domain name . Mysugarwatch.com now goes to Sugarwatch.uk

[BigBill1]

@WhiskeyBusiness Operational in what way?

[WhiskyBusiness]

Looks like Sugarwatch.uk domain operational now

[WhiskyBusiness]

Wonder if one of the stock promoters paying themselves before quarterly report?

[BigBill1]

Almost 90% of the 84 trades this morning were sell orders, not exactly something to get all excited about.
What I did find interesting is how the SP price rose 2.7% despite overwhelming selling.

[WhiskyBusiness]

Good point . Also interesting volume this morning

[BigBill1]

Just had a thought. The people in the UK that see this and similar articles about sugarBeat...do they have a way of knowing that it will be sold in Europe as MySugarWatch?? Is there a conspicuous link on Nemaura's website that redirects consumers to DBE?
I wonder how much revenue is going to be lost because of the stupid private label agreement?

[WhiskyBusiness]

Agree 100% with that . It's a good sign , shows you what is possible. Look forward to more exposure like this leading up to launch .

[BigBill1]

Lets see... 81.3 million monthly US visitors to that website. 9.4% are diabetic. So aprox 7.6 million diabetics may have seen the article. Maybe higher as it's a health orientated website. That's a lot of exposure!

This is actually the single best piece of news I've seen since I started investing in this stock a year and a half ago. Too bad it's a mostly wasted opportunity due to the delays.

[WhiskyBusiness]

Good find and thanks for posting ! 81.3 million visitors per month , good exposure. Monthly cost looks attractive .

[BigBill1]

@ Dia bet Another great find, this article contains a lot of new info. Here's my take on a a few things I found interesting:

1) "Meanwhile, Nemaura is predicting that its system may cost less than one-fifth of competing products:
$30 per month annual subscription plan for non-insulin users -- includes 8 patches/month, transmitter and recharger
$55 per month annual subscription for insulin users -- includes 16 patches/month, transmitter and recharger"

Finally,prices! Is 16 patches enough for insulin users?? Not for me. I hope the subscription is more flexible regarding quantity.

2) "However, EASD study did not publish the accuracy data associated with the important low blood sugar zone of <80 mg/dL. In this January 2018 presentation, SugarBEAT’s MARD was 19.28% in the 61-80 mg/dL range, and 26.92% in the 40-60 mg/dL range."

"They do expect accuracy to improve as the product matures."

This might possibly be a barrier to FDA approval as low sugar levels are much more dangerous then high levels. At the US Dept of Veteran Affairs GCMs are approved based solely on low sugar levels.

[Dia bet]

https://www.healthline.com/diabetesmine/non-invasive-sugarbeat-cgm-diabetes

[Think4yourself1]

Ha ha it said product available SOON in Europe, Australia, and the mid east. I wonder why whoever put that video on youtube why they eliminate comments? Maybe because it's people in the know that it's a bunch of bs and they dont want us to call them out on it. DBE was one of or the worst thing that Nemaura did allowing them to market in all of Europe. Get ready everyone for a reverse stock split or nasdaq delisting in January. It should of never came to this.

[WhiskyBusiness]

posted today but not new material for Nemaura-philes , activity nonetheless

[Think4yourself1]

How does FDA approval go from a estamite 90 days till now the end of 2020?

[WhiskyBusiness]

By end of year 2020 FDA decision mentioned in recent interview with Dr Schaebsdau and most recent corporate presentation on Nemaura website.

[MarketGeometry]

Where you seeing this news of end of next year Approval ?

[Think4yourself1]

I feel sorry for everyone who invested heavily in this company. Future does not look good. Nasdaq delisting or reverse stock split coming in January. What in the hell did faz see in DBE to let them market this product in all of Europe? Who else are DBE clients, and I wonder what they think of them? I would almost guarentee it that the scheduled early 2020 launch gets pushed back it's the nemaura way. Before I gave them some slack because of not being ce approved but now no excuses they had plenty of time to prepare. Mid east customers they promised will go to someone else now. Most horrible stock I ever owned. I will hold the shares I got let them go bankrupt before I sell.

[YMYBH]

Fascinating convo with Vice President #NemauraMedical about their non invasive glucose monitoring devices, plans and future aims #SugarBeat

Interesting times indeed @DTN_UK @JDRFUK @DiabetesUK @NHSDiabetesProg @Tims_Pants @cahmn #Technology #Diabetes pic.twitter.com/FDXNV7y80s

— Partha S Kar 🇮🇳🇬🇧🏏🎥 (@parthaskar) October 16, 2019

[YMYBH]

https://diabetestimes.co.uk/nhs-england-reappoints-partha-and-jonathan/

[iddrisw]

@bigbill. You have been right about DBE all along. I eat a crow on this one. They have faz by the balls else they should be fired. For a D2C model, nmrd could go it alone on amazon. It is telling that they have not even figured out the WAC price at this stage.

[BigBill1]

@Think4 Along that line I find it interesting why Dr. Fred is doing all the talking when DBE's flunky Chris Avery outranks him. Avery is Vice President of Global Business Operations at Nemaura. Dr. Fred is Vice President of Strategy & Strategic Alliances.

Because Avery was working in Dallas Burstons interest I have no idea why DBE dumped him unto Nemaura's payroll. Burston obviously wanted to get rid of him. On his LinkedIn profile Avery takes credit for developing MySugarWatch's website, a website which he failed to create before he left.

[Think4yourself1]

It's funny how nemaura has Dr. Fred talk about the upcoming launch because faz's. Credibility is destroyed. Investors will not be fooled this time.

[BigBill1]

@iddrisw I concur with your prediction. If only that idiot Dallas Burston would step up and launch by mid December some of this could be avoided.

With privately owned Nemaura Pharma having 16 items in the pipeline and Dallas Burston focused on a $100 million renovation of his namesake business, none of the principals involved will ever devote more than a part time attention to this product.

[iddrisw]

This stock is pretty much headed back to otc markets and further dilution. They conveniently left out cash position in the latest presentation for obvious reasons. If the sp goes to $1, then atm tap opens.

[BigBill1]

I'm guessing that Nemaura has already received some negative feedback from FDA, which is why they are now projecting approval & US launch by the end of next year.

[WhiskyBusiness]

No the corporate presentation on Nemaura's website. It's been updated for October and it's definitely a more polished presentation.